ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June
ADC Therapeutics is expecting top-line data from its LOTIS-5 trial by the end of June, with the goal of achieving $600M-$1B in peak US ZYNLONTA revenue. This financial target and the upcoming data release are key focus areas for the company.
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics has released its third-quarter 2025 financial results and provided an operational update. This information was highlighted by Quantisnow, a platform that provides real-time market data to retail investors. The update was delivered quickly to Quantisnow Plus members, indicating its timely distribution to subscribers.
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics has released its third-quarter 2025 financial results and provided an operational update. The report was distributed via Quantisnow, a platform that provides real-time market data and news for investors. Quantisnow Plus members received an alert shortly after the publication of the results.
HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ADC Therapeutics (ADCT) and maintained a price target of $17.00. This affirmation follows the recent FDA approval of Zynlonta for follicular lymphoma, a label expansion that is expected to significantly boost the drug's commercial potential. The analyst's positive outlook is driven by anticipated increased prescription volumes and broader market uptake, projecting Zynlonta sales to exceed $440 million by 2028.
Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst
HC Wainwright analyst R. Burns has decreased the Q2 2026 EPS estimate for ADC Therapeutics (NYSE:ADCT) to ($0.19) from ($0.17), while maintaining a "Buy" rating and an $8 price target. The company recently missed its Q1 EPS consensus, reporting ($0.21) versus an expected ($0.19), although revenue exceeded estimates. Significant insider selling has also been noted, with major shareholder Redmile Group selling over 2.6 million shares and other insiders selling a total of 5.88 million shares in the past three months.
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report
ADC Therapeutics SA (NYSE:ADCT) recently released its Q1 results, showing revenues slightly ahead of expectations but statutory earnings below consensus with a loss of US$0.21 per share. Analysts have maintained revenue forecasts for 2026 at US$81.4 million but increased loss expectations to US$0.85 per share. The stock's price target remained at US$8.20, suggesting that increased forecast losses are not expected to impact long-term valuation significantly, despite the company's revenue growth being projected to slow compared to historical rates and the broader industry.
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT)
ADC Therapeutics (ADCT) is rated a "Strong Buy" due to the potential of its drug ZYNLONTA in treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Key upcoming catalysts include topline data from the Phase 3 LOTIS-5 trial in Q2 2026 and further data from the Phase 1b LOTIS-7 trial by the end of 2026, which has already shown high response rates. The company also maintains a solid cash runway extending into 2028, reducing immediate dilution risks.
ADC Therapeutics SA 2026 Q1 - Results - Earnings Call Presentation (NYSE:ADCT) 2026-05-05
ADC Therapeutics SA has released its Q1 2026 earnings call presentation. The company published a slide deck to accompany the call, providing details on their financial results. This presentation is available to investors and was written by the SA Transcripts team.
ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics (NYSE:ADCT) held its Q1 2026 earnings call, reporting slightly increased net product revenues of $20 million for ZYNLONTA compared to Q1 2025, though missing EPS expectations. The company emphasized its operational progress and strict capital discipline, maintaining a cash runway into 2028. Key upcoming milestones include the LOTIS-5 top-line data readout expected by the end of June, which, if positive, could significantly expand ZYNLONTA's market to earlier lines of therapy and indolent lymphomas, potentially achieving peak annual revenues of $600 million to $1 billion in the U.S.
ADC Therapeutics to Host First Quarter 2026 Financial Results Co
ADC Therapeutics SA (NYSE: ADCT) announced it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to discuss its first-quarter 2026 financial results and provide operational updates. The company, a commercial-stage leader in antibody drug conjugates, will offer access details for the call and webcast through its investor relations website.
ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M
ADC Therapeutics reported Q1 2026 net revenue of $20.9 million and a net loss of $33.0 million, an improvement from the previous year. The company's U.S. ZYNLONTA product sales increased by 15.1% to $20.0 million, driven by higher volume and pricing, even as overall revenue decreased due to the absence of a prior-year milestone payment. Despite a leveraged capital structure with significant deferred royalty obligations and senior secured term loans, ADC Therapeutics maintains a cash balance of $231.0 million, supported by reduced research and development expenses following a 2025 restructuring.
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics (NYSE: ADCT) reported its first quarter 2026 financial results, including net product revenue of $20.0 million and cash and cash equivalents of $231.0 million with a projected runway into 2028. The company anticipates key clinical trial data releases in the second quarter and by year-end 2026 for its ZYNLONTA program, aiming to expand its role in B-cell malignancies. Despite a decrease in license revenues, the company reduced its net loss to $33.0 million, demonstrating progress in operational efficiency and clinical development.
ADC Therapeutics Releases Q1 2026 Financial Results
ADC Therapeutics SA reported a narrower-than-expected loss for the first quarter of 2026, with an adjusted loss of $0.13 per share against an estimated $0.20 loss. Despite the beat on EPS, revenue declined 9.5% year-over-year to $20.9 million, facing ongoing challenges in the competitive oncology therapeutics landscape. The company's net loss for the quarter was $19.7 million, focusing on developing targeted cancer therapies.
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary
ADC Therapeutics (ADCT) reported a 15% year-over-year revenue growth in Q1 2026, primarily due to customer ordering variability. The company is advancing its lifecycle management strategy for ZYNLONTA, targeting significant peak U.S. annual revenues and expects top-line data from the LOTIS-5 Phase III trial by June 2026, with an accelerated revenue growth trajectory anticipated from 2027 onwards following positive clinical readouts and regulatory approvals. Operational efficiencies were achieved through a 13% reduction in non-GAAP operating expenses, supported by a cash balance projected to fund operations into 2028.
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics SA (ADCT) reported a smaller-than-expected Q1 loss of $0.21 per share, beating the Zacks Consensus Estimate of a $0.19 loss. The company also surpassed revenue estimates, posting $20.85 million against a consensus of $19.74 million. Despite a year-over-year revenue decrease, ADC Therapeutics shares have gained 8.5% year-to-date, and the stock currently holds a Zacks Rank #2 (Buy).
ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028
ADC Therapeutics (NYSE: ADCT) reported its first-quarter 2026 financial results, showing a narrowed net loss of $33.0 million compared to $38.6 million in Q1 2025, driven by reduced R&D spending. Net product revenue from ZYNLONTA increased to $20.0 million, and the company projects its cash reserves of $231.0 million will fund operations at least into 2028. Key upcoming milestones include topline LOTIS-5 Phase 3 data in Q2 2026 and full data for both LOTIS-5 and LOTIS-7 by year-end.
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported first-quarter 2026 net product revenue of $20.0 million and maintains a cash runway at least into 2028. Key upcoming milestones include topline data from the LOTIS-5 Phase 3 trial in Q2 2026, with full data for LOTIS-5 and LOTIS-7 expected by year-end. The company is also advancing investigator-initiated trials for ZYNLONTA in additional B-cell malignancies, aiming to expand its role across these cancers.
Two new hires at ADC Therapeutics receive 49,400 stock options
ADC Therapeutics (ADCT) granted options to purchase 49,400 common shares to two new employees on May 1, 2026, as inducement under its Inducement Plan. These grants, approved by the Compensation Committee, vest 25% on the first anniversary and then monthly, with full vesting after four years, contingent on continued employment. The company utilized the NYSE employment inducement exemption (Rule 303A.08) for these grants.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT) announced on May 1, 2026, the grant of options to purchase 49,400 common shares to two new employees. These grants serve as a material inducement for their employment and were approved by the Compensation Committee under the Company's Inducement Plan. The options will vest over four years, subject to continued employment.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT) announced on May 1, 2026, grants of options to purchase an aggregate of 49,400 common shares to two new employees. These grants serve as a material inducement for their employment, approved by the Company's Compensation Committee under its Inducement Plan. The shares will vest over four years, subject to continued employment, in accordance with NYSE's Listed Company Manual Rule 303A.08.
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday
ADC Therapeutics (ADCT) is expected to announce its Q1 2026 earnings before the market opens on Monday, May 4th, with analysts forecasting an EPS of ($0.19) and revenue of approximately $19.99 million. The company has seen significant insider selling, including a major shareholder reducing their stake by over 17%, and institutional investors have adjusted their positions. While analysts have a "Moderate Buy" consensus, the stock has experienced recent fluctuations.
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
ADC Therapeutics (NYSE: ADCT) announced it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to discuss its first quarter 2026 financial results and provide operational updates. The company is a global leader in antibody drug conjugates, known for its treatment ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma. Interested parties can register for the call or access the webcast via the investor section of their website.
ADC Therapeutics schedules May 4 webcast on Q1 results and operations
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to discuss its first-quarter 2026 financial results and provide operational updates. The company, a leader in antibody drug conjugates (ADCs), will make the webcast available on its investor relations website, with an archived version accessible for 30 days. This follows a consistent pattern of quarterly earnings calls, which historically have been accompanied by modest, often negative, single-digit stock price movements.
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance
ADC Therapeutics is projecting peak revenue for its drug ZYNLONTA to be between $600 million and $1 billion. This forecast comes as two of the company's clinical trials, LOTIS-5 and LOTIS-7, are progressing, indicating future developments for the drug's market potential.
Redmile Group (NASDAQ: ADCT) reports 9.9% stake after SPV reorg
Redmile Group, LLC has disclosed a 9.9% beneficial ownership stake in ADC Therapeutics (NASDAQ: ADCT) following an internal reorganization. This reorganization involved RedCo II Master Fund, L.P. transferring its securities to its wholly-owned SPVs, with RedCo II Offshore SPV LLC now holding 6.1% of ADCT shares. The filing also clarifies that Redmile Group and Jeremy C. Green disclaim direct beneficial ownership beyond their pecuniary interest, and the reported percentage accounts for a Beneficial Ownership Limitation related to pre-funded warrants.
ADC Therapeutics S.A. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into potential securities fraud involving ADC Therapeutics S.A. (NYSE: ADCT) following a significant drop in its stock price. The investigation stems from safety concerns related to the company's oncology therapeutic clinical development program, specifically updated data from the LOTIS-7 Phase 1b trial and adverse events observed with ZYNLONTA® in combination with glofitamab. Investors are encouraged to contact the firm to discuss their legal rights.
ADC Therapeutics S.A. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into ADC Therapeutics S.A. (NYSE: ADCT) for potential securities fraud. This investigation follows a significant stock price drop on December 3, 2025, after the company disclosed safety concerns from their LOTIS-7 Phase 1b clinical trial, particularly regarding adverse events and immune-related side effects from ZYNLONTA® combined with glofitamab. The firm is encouraging investors to contact them to discuss their legal rights and potential class action.
ADC Therapeutics SA ($ADCT) CEO 2025 Pay Revealed
The CEO of ADC Therapeutics SA ($ADCT), Ameet Mallik, is estimated to have received $2,453,150 in compensation in 2025, a 25.09% increase from 2024. This estimate is based on a recent DEF14A SEC filing. Insider trading activity for ADCT shows 6 sales by GROUP, LLC REDMILE in the past 6 months, while hedge fund activity indicates that 62 institutional investors increased their positions and 43 decreased them in the most recent quarter.
Executive pay, equity plan and capital changes at ADC Therapeutics (ADCT)
ADC Therapeutics (ADCT) is holding its 2026 annual meeting on June 1, 2026, where shareholders will vote on key governance, compensation, and capital matters, including the reelection of directors and an increase in the 2019 Equity Incentive Plan's authorized shares. The company achieved 125% of its 2025 corporate goals, driven by strong Zynlonta sales and clinical program advancements, leading to above-target bonuses for executives. Shareholders will also consider significant amendments to the company's articles of association to expand its capital range and conditional share capital.
ADC Therapeutics (NASDAQ: ADCT) adds SILV Fund as selling shareholder
ADC Therapeutics (NASDAQ: ADCT) has updated its prospectus, confirming that 27,726,052 common shares remain registered for resale. This update includes the transfer of 1,383,144 shares from Point72 Associates, LLC to SILV Fund Ltd., making SILV Fund Ltd. a new selling shareholder. The aggregate number of registered shares for resale remains unchanged.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADC Therapeutics (NYSE: ADCT) announced its fourth quarter and full year 2025 financial results, reporting net product revenues of $22.3 million and $73.6 million, respectively, and a reduced net loss of $6.4 million for Q4 2025. The company also provided operational updates, including anticipated topline data from the LOTIS-5 Phase 3 trial in Q2 2026 and full results by year-end 2026, and highlighted its cash and cash equivalents of $261.3 million, providing an expected cash runway extending at least into 2028. Additionally, an amendment to the HealthCare Royalty financing agreement was reported, increasing strategic flexibility by reducing the change of control payment.
ADC Therapeutics (NYSE: ADCT) to hold virtual AGM June 1; votes on capital and pay
ADC Therapeutics (NYSE: ADCT) announced its 2026 Annual General Meeting (AGM) will be held virtually on June 1, 2026. Shareholders will vote on 12 proposals, including the re-election of directors and auditors, and amendments to increase authorized and conditional share capital. The proxy materials also disclose executive compensation frameworks for 2025, noting a 125% AIP payout and recent RSU grants to named executives.
ADCT.N Stock News Today | Earnings, Events & Price Alerts
The article provides news and event updates for ADCT.N (ADC Therapeutics), including recent Q4 2025 earnings reports and an upcoming investor conference schedule. Key financial data reveals a Q4 revenue beat and a cash runway expected to last into 2028. Additionally, the company is preparing for significant clinical trial results and potential regulatory approvals for its ZYNLONTA program.
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 169,265 Shares of Stock
Redmile Group, a major shareholder in ADC Therapeutics (NYSE:ADCT), sold multiple blocks of ADCT stock between March 31 and April 2, totaling approximately 5.9 million shares for about $19.6 million. Despite these sales, Redmile Group still holds around 15.3 million shares. ADC Therapeutics currently trades near $3.81 and has a "Moderate Buy" consensus analyst rating with an average target of $7.67, though the company remains loss-making.
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells $8,641,179.68 in Stock
Redmile Group, a major shareholder in ADC Therapeutics (NYSE:ADCT), sold over 2.6 million shares totaling $8.6 million on April 2nd, 2026, reducing its stake by 17.22%. Despite the insider selling, ADC Therapeutics maintains a "Moderate Buy" rating from analysts with an average target price of $7.67. The company, a clinical-stage biopharmaceutical firm focusing on antibody-drug conjugates, has seen mixed institutional trading and currently trades at $3.81 with a market cap of $483.39 million.
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 196,229 Shares of Stock
A major shareholder of ADC Therapeutics (NYSE:ADCT), Redmile Group, Llc, recently sold a significant number of shares, including 196,229 shares on March 31st and additional large blocks on April 2nd, reducing its ownership by 1.25%. Despite these insider sales totaling millions of dollars, ADCT's stock remained relatively flat, and analysts maintain a "Moderate Buy" rating with an average target price of $7.67. ADC Therapeutics is a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates for treating hematological malignancies.
Redmile-managed funds trim ADC Therapeutics (ADCT) stake with 5.9M-share sale
Funds managed by Redmile Group sold a total of 5,880,415 shares of ADC Therapeutics (ADCT) common stock in open-market transactions between March 31 and April 2, 2026. The sales occurred at weighted average prices ranging from approximately $3.28 to $3.80 per share. Despite these significant sales, Redmile-managed entities still retain a substantial position in ADC Therapeutics, totaling over 22 million shares across direct and indirect holdings.
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA announced the grant of options to purchase 17,000 common shares to a new employee as a material inducement for their employment. This grant was approved by the Compensation Committee under the Company's Inducement Plan and vests over four years, subject to continued employment. The company issued this press release in compliance with NYSE's Listed Company Manual Rule 303A.08.
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance
ADC Therapeutics is projecting peak annual revenue for its drug ZYNLONTA to be between $600 million and $1 billion. This forecast is based on the advancing clinical trials LOTIS-5 and LOTIS-7, which are assessing ZYNLONTA's potential to establish itself as a frontline treatment option. The company is actively working to expand the drug's label into earlier lines of therapy.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
This article analyzes whether Acumen Pharmaceuticals (ABOS) and ADC Therapeutics SA (ADCT) are outperforming their medical sector peers. Both companies are highlighted for their positive year-to-date returns compared to the sector's average loss. The analysis uses Zacks Rank and consensus EPS estimates to suggest their continued strong performance.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADC Therapeutics (NYSE: ADCT) reported its fourth quarter and full year 2025 financial results, highlighting net product revenues of $22.3 million for Q4 and $73.6 million for the full year. The company expects topline data from its LOTIS-5 Phase 3 trial in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026, and maintains a cash runway at least into 2028. An amendment to its HealthCare Royalty financing agreement has also increased strategic flexibility.
ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat
ADC Therapeutics is strategically focusing on expanding its CD19-directed antibody-drug conjugate ZYNLONTA into earlier lines of Diffuse Large B-cell Lymphoma (DLBCL) and indolent lymphomas, moving beyond its current third-line approval. Key to this expansion are the upcoming top-line data from the Phase III LOTIS-5 study, expected in Q2, which could significantly increase the addressable patient population and drive revenue growth. Additionally, promising early data from the Phase Ib LOTIS-7 study, combining ZYNLONTA with glofitamab, showed high response rates and reduced cytokine release syndrome, further supporting the drug's potential in combination therapies.
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade
ADC Therapeutics (NYSE:ADCT) shares gapped up after HC Wainwright raised its price target to $8 from $7, maintaining a "buy" rating. The stock opened at $4.10, up from a prior close of $3.86, and is trading around $4.00. The company recently reported an earnings beat, with EPS of -$0.04 against an expected -$0.32, and revenue of $23.06 million versus $22.29 million, although it remains loss-making.
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00
HC Wainwright has raised its price target for ADC Therapeutics (NYSE:ADCT) to $8.00 from $7.00, maintaining a "buy" rating and suggesting a significant upside. The company recently surpassed analysts' estimates for both earnings and revenue in its latest quarterly report. The consensus among analysts for ADCT is a "Moderate Buy" with an average target price of $7.67.
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT
Heights Capital Management Inc. significantly reduced its stake in ADC Therapeutics (NYSE:ADCT) by 88.5% in Q3, now holding 326,766 shares valued at approximately $1.31 million. Despite this, other hedge funds increased their positions, and the company reported strong Q3 earnings, beating EPS estimates by $0.28. Analysts maintain a "Moderate Buy" rating for ADCT with an average price target of $7.33, while the stock trades around $4.11.
[EFFECT] ADC Therapeutics SA SEC Filing
ADC Therapeutics SA (ADCT) had an EFFECT filing declared effective on March 16, 2026, at 4:00 P.M. This filing is a Form S-3, with the CIK 0001771910 and file number 333-294191. The filing impact and sentiment are both neutral.
ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants
ADC Therapeutics (ADCT) has filed a resale prospectus to register 9,834,776 common shares, which are issuable upon the exercise of warrants previously issued to HealthCare Royalty Management, LLC (HCR) on February 18, 2026. While the company will not receive proceeds from the direct resale of these shares by the warrant holders, it could receive up to $37.5 million if the warrants are exercised for cash, with these funds designated for working capital and general corporate purposes. The warrants have an exercise price of $3.8130 per share and are exercisable until December 31, 2030, though transfer restrictions apply until December 31, 2027.
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
ADC Therapeutics announced that its drug ZYNLONTA has a peak U.S. revenue potential of $600 million to $1 billion. This projection is based on expanded clinical milestones, indicating strong future growth for the company's key therapeutic asset.
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
ADC Therapeutics announced that ZYNLONTA, its approved drug for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has a projected peak revenue potential in the U.S. of $600 million to $1 billion. The company also presented new clinical data and outlined plans for further development, including combination therapies and studies in new indications. These initiatives aim to expand ZYNLONTA's market reach and patient population.
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1%
ADC Therapeutics SA (ADCT) reported a wider Q4 2025 adjusted loss of $0.29 per share, missing the expected -$0.27. The company generated $22.3M in revenue for the quarter. ADC Therapeutics focuses on antibody drug conjugate technology, with its lead product ZYNLONTA having received accelerated approval from the U.S.
